They announced Q3 results without one mention of Relenza sales figures. GSK investors wouldn't be too phased about it though. A drop in the ocean for GSK.
Don't expect to hear anymore about orders unless the case is settled or may/june next year when the royalty cheque is in.
Unless of course it finds its way to the media as were the case with the most recent French order.
